Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7475 in Combination With ONO-4538 and GnP in Metastatic Pancreatic Cancer
NCT06532331Phase 1Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Dec 2023
- Primary completion
- Sep 2027
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1 trial of ONO-7475 (2 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Dose-limiting toxicities at 28 days and Adverse event. Started Dec 2023; status: active, not recruiting.
02
Drugs
ONO-7475
Beyond the preview
Go deeper on NCT06532331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532331.